# China NMPA Inspection - National Medical Products Administration - June 11, 2021

Source: https://www.globalkeysolutions.net/records/china_inspection/national-medical-products-administration/99cdcabe-08b6-4a55-a8f6-19b71da65eac/
Source feed: China

> China NMPA unannounced inspection for National Medical Products Administration published June 11, 2021. The Jilin Provincial Drug Administration issued an announcement on June 11, 2021, to standardize the filing of domestic general cosmetics and strength

---

## Details

- Record Type: CHINA_INSPECTION
- Title: Announcement from the Jilin Provincial Drug Administration on Regulating the Filing of Domestic General Cosmetics and Strengthening Supervision and Management of Cosmetic Registrants, Filers, and Contract Manufacturers
- Company Name: National Medical Products Administration
- Publication Date: 2021-06-11
- Product Type: cosmetics
- Summary: The Jilin Provincial Drug Administration issued an announcement on June 11, 2021, to standardize the filing of domestic general cosmetics and strengthen oversight of registrants, filers, and contract manufacturers. This initiative implements new regulatory frameworks, including the *Cosmetics Supervision and Management Regulations* and *Cosmetics Registration and Filing Management Measures*, which became effective on May 1, 2021. Companies are now legally responsible for product quality, safety, and efficacy claims, requiring scientific evidence and public disclosure. 

Key obligations include operating under Good Manufacturing Practices (GMP), establishing comprehensive quality management systems, appointing a qualified quality and safety officer, and managing employee health. New filing procedures for general cosmetics mandate submission of safety and quality materials via the Cosmetic Registration and Filing Information Service Platform from May 1, 2021. Companies must also evaluate efficacy claims and submit safety assessments by deadlines extending to May 2024. Arbitrary changes to product names, efficacy claims, or formulas are prohibited.

Supervision by the Provincial Drug Administration and local authorities will be rigorous, allowing for orders of rectification, sales suspension, or registration cancellation for non-compliance, with severe penalties for providing false information. Filers must rectify any deficiencies from the old platform by September 15, 2021, to avoid filing cancellation. The regulatory framework emphasizes risk-based management and annual reporting to ensure heightened industry compliance in Jilin.

Company: https://www.globalkeysolutions.net/companies/national-medical-products-administration/6e6c9c0b-c8e5-4330-aec0-ab84e891e2fd/